Abstract
Problem How do we manage treatment and stabilization in clinical settings and static population communities like assisted living facility settings of their patient or resident populations during and post the SARS-CoV-2 pandemic?
Scope This proposal explores the possible and predicted changes to standard operating procedures to the facility management and associated landscape and focuses on series of deployments, during and post peak SARS-CoV-2 activity, and will outline possible models for the current medical facility model that we operate with. This article primarily focuses on non-emergency facility management.
Assumptions and understanding of the field With a reduction in the numbers nationally, patients are highly motivated and likely to seek non-emergency and planned medical procedural treatment as early as possible as social distancing measures are eased and restrictions on non-urgent procedures are lifted.
Conclusions and next steps An initial pan-national shutdown and suspension of services was necessary in an effort to ensure that essential medical services and resources were not strained. The authors feel that a strategic resumption of regular non-emergency treatments around the United States and continued provision of services at care facilities is possible with innovative testing strategies like pooled screening of large populations at a manageable price point. Moreover, pooling as a strategy when used widely, would be extremely effective at predicting outbreaks of the virus and as an effect help in mitigating the spread of the virus in its “second-wave”. We have developed one such innovative pooling strategy that can be easily deployed across laboratories and reduce the cost of population wide COVID-19 testing significantly
Competing Interest Statement
S. Sawarkar, S. Verma, J. Sams, and S. Haran are founders at Rosa Scientific. M. Viotti, A. Victor are employed at Zouves Foundation for Reproductive Medicine
Funding Statement
Our research was supported by funding from ZFRM and Rosa Scientific
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was waived from the review by the Zouves Foundation Institutional Review Board (OHRP IRB00011505).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is submitted and available on request